Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00604123 | A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults | PHASE2 | COMPLETED | 74 | — | — | Jan 1, 2008 | Feb 1, 2008 | Apr 29, 2015 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| JNJ-17166864 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ-17166864 | DRUG | JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks. |
| Placebo | DRUG | Placebo nasal spray twice daily for 2 weeks. |
Inclusion Criteria: * Have a clinical history of seasonal allergic rhinitis with onset and offset of nasal allergy symptoms during each of the past 2 mountain cedar allergy seasons * Have positive prick skin test reaction to mountain cedar allergen at screening or have a documented positive prick s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |